Related Experiment Videos
[Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study]
L Cartier1, J L Castillo, R Verdugo
1Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile (Campus Oriente), Hospital del Salvador, Santiago de Chile.
Background:
Idiopatic or HTLV-1 associated progressive spastic paraparesis does not have a clear etiology or treatment.
Aim:
To assess the effects of a medication containing cytidinmonophosphate, uridintriphosphate and vitamin B 12 in the treatment of progressive spastic.
Patients And Methods:
Patients with the disease were randomly assigned to receive the Nucleus CMP forte (containing dysodic cytidinmonophosphate 5 mg, trisodic uridintriphosphate 3 mg and hydroxicobalamin 2 Mg) tid or placebo during six months. Gait, spasticity, degree of neurogenic bladder and somatosensitive evoked potentials were assessed during treatment.
Results:
Forty six patients aged 25 to 79 years old were studied, 24 were female and 29 HTLV-1 positive. Twenty two were treated with the drug and the rest with placebo. Gait and spasticity improved in 7 of 22 patients receiving the drug and 1 of 24 receiving placebo (p < 0.05). Neurogenic bladder improved in 10 of 22 receiving the drug and 4 of 24 receiving placebo (NS) Somatosensitive evoked potentials improved in four of seven patients treated with the drug and in two of seven treated with placebo.
Conclusions:
The medication caused a modest improvement in patients with progressive spastic paraparesis and was free of side effects.